<DOC>
	<DOCNO>NCT01114464</DOCNO>
	<brief_summary>The aim protocol study deleterious impact adjuvant chemotherapy neoadjuvant chemotherapy ovarian reserve young woman suffer breast cancer . A new relevant ovarian reserve marker , serum Anti-Mullerian Hormone , use order evaluate precisely impact chemotherapy ovary chemotherapy administration follow-up ( 24 month ) . This strategy offer 2 main advantage : modification traditional care patient ( treatment , organisation , follow â€¦ ) use non invasive marker ( serum ) . The final objective give precise information patient future fertility remission .</brief_summary>
	<brief_title>Impact Chemotherapy Ovarian Reserve Young Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>female 1839 year suffer breast cancer treat adjuvant neoadjuvant chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Ovarian reserve</keyword>
	<keyword>Anti-Mullerian Hormone ( AMH )</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>